Sriram Balasubramanian

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson et al. · Journal of Clinical Oncology · 2019 · 616 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Yibin Yang, Arthur L. Shaffer, N. C. Tolga Emre et al. · Cancer Cell · 2012 · 514 citations · Full text

Medicine, Oncology, Pharmacology +12

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 462 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Sriram Balasubramanian, Jason Ramos, Weigang Luo et al. · Leukemia · 2008 · 446 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Immunology, Pharmacotherapy +12